Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
P/Q-Type Calcium Channel Blockade Modulates Apoptosis in Epi
2026-06-02
The reference study demonstrates that selective inhibition of P/Q-type (Cav2.1) calcium channels with ω-agatoxin IVA reduces seizure activity and modulates key apoptotic and neurotrophic markers in a rat model of epileptogenesis. These findings highlight a mechanistic link between calcium channel blockade, neuronal survival, and seizure suppression, advancing the search for novel antiepileptic targets.
-
Q-VD(OMe)-OPh: Precision Caspase Inhibition for Apoptosis As
2026-06-01
Q-VD(OMe)-OPh provides unparalleled specificity and low cytotoxicity for apoptosis research, enabling high-fidelity cell death studies and resistance modeling. Applied in both cancer and neuroprotection workflows, this APExBIO inhibitor optimizes performance where conventional caspase inhibitors fall short.
-
Aprotinin (BPTI): Reliable Solutions for Cell Assay Integrit
2026-06-01
This article addresses key challenges in cell viability and cytotoxicity assays, demonstrating how Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI), SKU A2574, ensures reproducibility and assay fidelity. Drawing on evidence-backed scenarios and practical protocol guidance, we show why researchers should consider APExBIO's aprotinin as a trusted reagent for sensitive protease-inhibition workflows.
-
Thiothixene: Typical Antipsychotic Agent for Research Innova
2026-05-31
Thiothixene stands out as a typical antipsychotic agent with validated roles in both neuropharmacology and immunology research. Its unique ability to modulate dopamine signaling and enhance macrophage efferocytosis—independent of CYP2D6 interactions—makes it a versatile tool for advanced experimental design and troubleshooting.
-
WY-14643 (Pirinixic Acid): PPARα Agonism and Tumor Microenvi
2026-05-30
Explore how WY-14643 (Pirinixic Acid), a selective PPARα agonist, uniquely enables targeted metabolic and tumor microenvironment research. This article reveals advanced mechanistic insights and practical assay guidance not found in existing reviews.
-
Alfuzosin HCl in BPH Research: Optimized Protocols & Insight
2026-05-29
Alfuzosin HCl delivers high-fidelity modeling of prostatic smooth muscle relaxation, enabling robust inhibition of intraurethral pressure with minimized cardiovascular interference. This guide details experimental workflows, troubleshooting, and the pivotal innovations that set APExBIO’s Alfuzosin Hydrochloride apart for benign prostatic hyperplasia research.
-
P2Y2 Receptor Activation Enhances Microglial Aβ Clearance in
2026-05-29
Kim et al. demonstrated that nucleotides released from Aβ1–42-exposed microglial cells stimulate P2Y2 receptor signaling, which in turn enhances microglial migration and β-amyloid uptake. This mechanistic insight highlights P2Y2R as a candidate therapeutic target for improving amyloid clearance in Alzheimer's disease and refines our understanding of microglial dynamics in neurodegeneration.
-
Ficolin 3 Drives Ferroptosis Sensitivity in HCC via MUFA Reg
2026-05-28
Yuan et al. (2024) reveal that Ficolin 3 (FCN3) enhances ferroptosis in hepatocellular carcinoma (HCC) by inhibiting MUFA synthesis through direct modulation of the IR/SREBP axis. This mechanistic insight highlights new therapeutic strategies targeting lipid metabolism to overcome ferroptosis resistance in HCC.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Precision Tracking and A
2026-05-28
Explore how EZ Cap Cy5 Firefly Luciferase mRNA enables dual-modality tracking and advanced translation efficiency assays. Discover new insights into mRNA delivery, stability, and practical protocol design, distinguishing this guide from standard product rundowns.
-
Aprotinin (BPTI): Mechanistic Insights for Blood Management
2026-05-27
Explore how Aprotinin, a bovine pancreatic trypsin inhibitor, advances blood management research by combining precise serine protease inhibition with new mechanistic insights from membrane biophysics. This article bridges molecular action with emergent applications in perioperative and cardiovascular settings.
-
Acifran: Structural Selectivity and Assay Innovation in Lipi
2026-05-27
Explore how Acifran, a selective (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is transforming lipid metabolism research through structural selectivity insights and practical assay optimization. This article delivers a fresh, in-depth analysis of Acifran's molecular interactions, bridging cryo-EM findings to actionable scientific workflows.
-
Refining In Vitro Drug Response Metrics in Cancer Research
2026-05-26
Schwartz's dissertation introduces a more nuanced framework for evaluating anti-cancer drug responses in vitro by distinguishing between proliferative arrest and cell death. This approach clarifies the interpretation of apoptosis inhibitor effects and guides more predictive preclinical study designs.
-
AT-406 (SM-406): Advanced Insights into IAP Antagonism and A
2026-05-26
Explore how AT-406 (SM-406) uniquely targets inhibitor of apoptosis proteins, enabling precise apoptosis pathway activation in cancer cells. This article offers a deeper protocol-based perspective and integrates the latest structural biology findings for optimal research design.
-
(S)-(+)-Ibuprofen: Precision COX Inhibitor for Lab Research
2026-05-25
(S)-(+)-Ibuprofen from APExBIO sets a new standard in selective COX inhibition, empowering researchers to dissect inflammation and pain pathways with high reproducibility. Discover advanced experimental workflows, troubleshooting strategies, and unique insights from recent toxicology studies to maximize your assay success.
-
SU 5402 in Cancer & Neuronal Models: Protocols and Pitfalls
2026-05-25
SU 5402 stands out as a multi-targeted receptor tyrosine kinase inhibitor, enabling high-precision dissection of FGFR, VEGFR, and PDGFR pathways in cancer biology and neuronal disease research. This article details hands-on workflows, troubleshooting guidance, and strategic protocol enhancements for robust use in experimental models, highlighting nuanced insights from recent advances.
8363 records 12/558 page Previous Next First page 上5页 1112131415 下5页 Last page